Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.74 |
| ▸ | SRC | P12931 | 13/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.74 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.74 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.74 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.74 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.74 |
| ▸ | EGFR | P00533 | 6/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.74 |
| ▸ | PRKCG | P05129 | 3/20 | 0.74 |
| ▸ | PRKCB | P05771 | 3/20 | 0.74 |
| ▸ | PRKCA | P17252 | 3/20 | 0.74 |
| ▸ | PRKCH | P24723 | 3/20 | 0.74 |
| ▸ | PRKCI | P41743 | 3/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.74 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.74 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.74 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4792766 | 0.86 | FGFR1 (0.56) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL8135009 | 0.86 | FGFR1 (0.83) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL8124128 | 0.85 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL29382814 | 0.85 | FGFR1 (1.00) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL12394361 | 0.84 | FGFR1 (0.76) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL1167903 | 0.83 | FGFR1 (0.75) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL12862978 | 0.83 | FGFR1 (0.58) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL927776 | 0.82 | FGFR1 (0.53) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL31647907 | 0.81 | FGFR1 (0.75) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL8806085 | 0.80 | FGFR1 (0.70) | FGFR1SRCPDGFRBPDGFRAFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773835-B1 | PYRIDO-PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF FOR TREATING CANCER | SANOFI SA (FR) | 2014-09-24 | — | — | EP | disclosed |
| EP-2020410-B1 | Pyrido[2,3-d]pyrimidine derivatives, process for their preparation and their therapeutical use | SANOFI SA (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-8008310-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-8008310-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-7893259-B2 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-02-22 | — | — | US | disclosed |
| US-20090233923-A1 | PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | US | disclosed |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | US | disclosed |
| US-7544682-B2 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-06-09 | — | — | US | disclosed |
| US-7504406-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| US-7504406-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| EP-1902054-B1 | DERIVATIVES OF PYRIDO[2,3-D]PYRIMIDINE, THE PREPARATION THEREOF AND THE THERAPEUTIC APPLICATION OF THE SAME | SANOFI AVENTIS (FR) | 2009-02-18 | — | — | EP | disclosed |
| EP-2020410-A1 | Pyrido[2,3d]pyrimidine derivatives, process for their preparation and their therapeutical use | sanofi-aventis (FR) | 2009-02-04 | — | — | EP | disclosed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| EP-1773835-A2 | PYRIDO-PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF FOR TREATING CANCER | Sanofi-Aventis (FR) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007003765-A1 | DERIVATIVES OF PYRIDO[2,3-D]PYRIMIDINE, THE PREPARATION THEREOF, AND THE THERAPEUTIC APPLICATION OF THE SAME | SANOFI AVENTIS (FR) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006016067-A2 | PYRIDO-PYRIDO PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, THERAPEUTIC USE THEREOF FOR TREATING CANCER | SANOFI-AVENTIS (FR) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | DPYD, PNPO, TYMP | FGFR1 1336/4885SRC 4096/4885PDGFRB 499/4885 |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | FGFR1 2373/4885SRC 2431/4885PDGFRB 432/4885 |
| US-20090233923-A1 | PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | DPYD, PNPO, TYMP | FGFR1 1312/4885SRC 3854/4885PDGFRB 555/4885 |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | FGFR1 2373/4885SRC 2431/4885PDGFRB 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.